<?xml version="1.0" encoding="utf-8"?>
<feed xmlns="http://www.w3.org/2005/Atom"><title>ARPA-H director&#x27;s menopause-company stock and the hormone-therapy warning change (INV-069): updates, Public Trust Tracker</title><id>https://publictrusttracker.org/case/inv-069-arpa-h-directors-menopause-company-stock-and-the-hormone/</id><link href="https://publictrusttracker.org/case/inv-069-arpa-h-directors-menopause-company-stock-and-the-hormone/"/><link rel="self" href="https://publictrusttracker.org/case/inv-069-arpa-h-directors-menopause-company-stock-and-the-hormone/feed.xml"/><updated>2026-11-12T00:00:00Z</updated><author><name>Public Trust Tracker</name></author><entry><title>INV-069, 12 Nov 2026: (Allegation, Campaign Legal Center) The Campaign Legal Center asks HHS Inspector General…</title><id>https://publictrusttracker.org/case/inv-069-arpa-h-directors-menopause-company-stock-and-the-hormone/#2f704350da</id><link href="https://publictrusttracker.org/case/inv-069-arpa-h-directors-menopause-company-stock-and-the-hormone/"/><updated>2026-11-12T00:00:00Z</updated><summary>(Allegation, Campaign Legal Center) The Campaign Legal Center asks HHS Inspector General T. March Bell to investigate whether Jackson &quot;violated recusal requirements and financial disclosure laws&quot;, including by &quot;failing to recuse or obtain a conflicts of interest waiver&quot; before taking part in the removal of the &quot;black box&quot; warning on hormone therapies, and whether she fully disclosed her and her spouse&#x27;s interests in private investment funds. The complaint cites the criminal conflict-of-interest law (18 U.S.C. 208) and the Ethics in Government Act.</summary></entry><entry><title>INV-069, 29 Oct 2026: ProPublica reports that Jackson&#x27;s disclosures list $115,002 to $300,000 in Evernow stock…</title><id>https://publictrusttracker.org/case/inv-069-arpa-h-directors-menopause-company-stock-and-the-hormone/#715243de12</id><link href="https://publictrusttracker.org/case/inv-069-arpa-h-directors-menopause-company-stock-and-the-hormone/"/><updated>2026-10-29T00:00:00Z</updated><summary>ProPublica reports that Jackson&#x27;s disclosures list $115,002 to $300,000 in Evernow stock and options, that both disclosures remain uncertified, and that no ethics waiver for her appears in Office of Government Ethics records. HHS says she has been placed on administrative leave and that it will &quot;assess the facts before determining any change in her status.&quot;</summary></entry><entry><title>INV-069, 26 Oct 2026: Asked by Bloomberg Law about a limited conflict-of-interest waiver Jackson had sought,…</title><id>https://publictrusttracker.org/case/inv-069-arpa-h-directors-menopause-company-stock-and-the-hormone/#335c1b23b3</id><link href="https://publictrusttracker.org/case/inv-069-arpa-h-directors-menopause-company-stock-and-the-hormone/"/><updated>2026-10-26T00:00:00Z</updated><summary>Asked by Bloomberg Law about a limited conflict-of-interest waiver Jackson had sought, HHS Press Secretary Emily Hilliard says: &quot;Alicia Jackson is currently on administrative leave&quot;, without giving a reason. Bloomberg Law reports on a draft HHS memo, obtained through a records request in July, that would grant Jackson a limited waiver under 18 U.S.C. 208(b)(1). The undated, unsigned draft says that since joining in October 2025 she &quot;has been required to recuse from a significant portion of the duties&quot; of the director because of her financial interests, and that without a waiver she is limited to broad policy discussions on &quot;Make America Healthy Again&quot; and artificial intelligence. OGE and HHS records requests by Bloomberg Law produced no evidence of an approved waiver.</summary></entry></feed>
